From: A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
Parameter | N (%) |
---|---|
Age years (median, range) | 69 (44–85) |
Height | 168 cm (152–186) |
Weight | 69.5 kg (45–175) |
Gender | |
Male | 69 (68%) |
Female | 33 (32%) |
ECOG PS | |
0 | 53 (52%) |
1 | 41 (40%) |
2 | 8 (8%) |
Lung parenchyma metastasis | |
Yes | 68 (67%) |
No | 34 (34%) |
Lymph node metastasis | |
Yes | 72 (71%) |
No | 30 (29%) |
Loco-regional lymph node metastasis | |
Yes | 31 (30%) |
No | 71 (70%) |
Liver metastasis | |
Yes | 19 (19%) |
No | 83 (81%) |
Brain metastasis | |
Yes | 14 (14%) |
No | 88 (86%) |
Malignant pleural effusion | |
Yes | 9 (9%) |
No | 93 (91%) |
Bone metastasis | |
Yes | 27 (26%) |
No | 75 (74%) |
Adrenal gland metastasis | |
Yes | 11 (11%) |
No | 91 (89%) |
N. of metastatic sites | |
1 | 21 (21%) |
2 | 34 (33%) |
3 | 47 (46%) |